

Cerebral microbleeds and stroke: more questions than answers

Udaya K. Ranawaka¹

Sri Lanka Journal of Neurology, 2021, **8**, 10-14

Abstract

With the widespread availability of MRI scanning, cerebral microbleeds (CMBs) are being increasingly recognised in patients with stroke and in healthy individuals. As CMBs are commonly viewed as markers of increased risk of intracerebral haemorrhage (ICH), there are concerns regarding the use of antithrombotic agents (antiplatelets, and especially anticoagulants) in the presence of CMBs, even in patients at high risk of ischaemic events. The use of antiplatelet or anticoagulant therapy in the presence of CMBs, balancing the risk of recurrent ischaemic stroke against the risk of possible intracranial bleeding, is one of the most contentious contemporary issues in stroke medicine.

Key words: cerebral microbleeds; stroke; intracerebral haemorrhage; ischaemic stroke; antiplatelets; anticoagulants

What are cerebral microbleeds?

CMBs are a radiological biomarker of cerebral small vessel disease. They are seen on blood-sensitive MRI sequences such as T2*-weighted gradient-recalled echo (T2*-GRE) or susceptibility-weighted imaging (SWI)^{1,2,3,4,5,6}. They are small (usually <5 mm in diameter), rounded or oval lesions of low signal intensity in the brain parenchyma^{1,2,3,4,7,8}. CMBs represent hemosiderin deposits contained within macrophages in the microvascular perivascular spaces on histopathological examinations^{1,2,3,4,9}, and develop as a result of leakage of red blood cells secondary to rupture of the walls of small arteries, arterioles or capillaries^{1,2,10}. Whether the rupture of a small vessel results in a microbleed or a larger macrobleed is believed to depend on different vasculopathic features and environmental exposure^{5,7}. Two distinct patterns of microangiopathy are noted on histopathological testing in the blood vessels located near CMBs: lipohyalinosis and cerebral amyloid angiopathy (CAA). The pattern of microangiopathy appears to determine the pattern of anatomical distribution of CMBs;

lobar CMBs are associated with CAA in superficial perforating arteries, deep subcortical or infratentorial CMBs result from arteriosclerosis or lipohyalinosis related to hypertensive arteriopathy of deep perforating arteries, and a mixed distribution in both locations is seen with a mixed pattern of microangiopathy^{2,3,5,6,9,11}.

CMBs: What do they mean?

Prevalence of CMBs is highly variable, depending on the demographic and clinical characteristics of the population studied and the MRI criteria of assessment. They are reported in 3-27% of the general population, and 6-80% of patients with vascular risk factors or vascular disease². In population studies, CMBs were associated with older age, hypertension, diabetes, smoking and previous stroke^{2,3,6,12}.

CMBs and stroke

CMBs are more prevalent in patients with stroke, and in patients with ICH than ischaemic stroke^{1,2}. In a systematic review, CMBs were seen in 5% of healthy adults compared to 45% of patients with any stroke, 34% with ischaemic stroke and 60% with ICH¹².

CMBs predict increased stroke risk. In a meta-analysis, CMBs increased the risk of ischaemic stroke (odds ratio [OR]: 2.14), ICH (OR 4.65) and death (hazard ratio: 1.36)¹³. CMBs are a marker of small vessel disease. They are more frequent in patients with lacunar strokes than cortical strokes^{1,2,14,15,16}, and in those with a higher burden of white matter lesions (WMLs) in periventricular or deep white matter regions^{11,12,14}. CMBs are reported to be twice as frequent in patients with lacunar strokes (26%) than cortical strokes (13%)¹.

CMBs are commoner among patients with recurrent strokes than first-ever strokes^{12,17}. In pooled data from 54 studies, CMBs were seen in 23% with first-ever ischaemic stroke and 52% with first-ever ICH, compared to 44% with recurrent ischaemic stroke and 83% with recurrent ICH¹². The risk of stroke recurrence appears to be greater with lobar CMBs^{11,13,14}, and in the presence of ≥ 5 CMBs^{2,16,18}.

¹Faculty of Medicine, University of Kelaniya, Sri Lanka.

Correspondence: E-mail: udayaran@yahoo.com; udayaran@kln.ac.lk

In patients with atrial fibrillation (AF), CMBs are more prevalent^{19,20,21}, and are associated with ischaemic stroke^{19,20} and asymptomatic cerebral infarction²¹. They are reported in 30-56% of patients with AF and ischaemic stroke^{7,19,20,22}. Prior antiplatelet therapy is independently associated with the presence of CMBs in patients with AF²⁰. CMBs are also related to prior anticoagulation with warfarin in patients with AF, but not with non-vitamin K antagonist oral anticoagulants (NOACs)⁸.

CMBs and intracerebral haemorrhage

CMBs increase the risk of ICH, particularly in patients with multiple lobar CMBs (which indicates probable underlying CAA). In a meta-analysis of data from 10 studies involving ICH survivors, a consistent association between CMB presence at baseline and risk of future ICH recurrence was seen. The risk of recurrent ICH varied with the distribution and burden of CMBs, and the underlying microangiopathy⁷. In presumed CAA-related ICH (based on a lobar distribution of ICH), the risk of recurrent ICH was 7-fold higher compared to CAA-unrelated ICH; the risk was higher in those with CMBs (28.7%) compared to those without (11.3%), and in those with a higher CMB burden. Even in CAA-unrelated ICH, the risk of recurrent ICH was higher in those with CMBs (4.6%) compared to those without (1.2%), but only the presence of more than 10 CMBs was associated with an increased risk. The presence of a single CMB did not increase the risk of recurrent ICH⁷.

CMBs and ischaemic stroke

In patients with ischaemic stroke, CMBs increase the risk of both ischaemic and haemorrhagic stroke recurrence. In a meta-analysis of ten prospective cohorts with ischaemic stroke or TIA, the presence of CMBs was associated with an increased risk of recurrent stroke (OR 2.25), and the risk was greater for recurrent ICH (OR 8.52) than for recurrent ischaemic stroke (OR 1.55)¹¹. Pooled analysis of individual patient data from 38 cohort studies in the Microbleeds International Collaborative Network showed that in patients with previous ischaemic stroke or TIA, the presence of CMBs on baseline neuroimaging was associated with increased risk of both ischaemic stroke and ICH, and the risk of ICH was higher than that of ischaemic stroke. The adjusted hazard ratio (comparing patients with CMBs vs. no CMBs) was 1.35 for any stroke, 2.45 for ICH and 1.23 for ischaemic stroke. The CMB burden correlated with the comparative risks of ICH and ischaemic stroke, with the risk of ICH 5 times higher than the risk of ischaemic stroke in the presence of ≥ 10 CMBs, and 8 times higher with ≥ 20 CMBs¹⁰. However, the absolute rate of ischaemic stroke consistently exceeded that of ICH, irrespective of age, CMB anatomical distribution, CMB burden, antithrombotic treatment and a diagnosis of probable cerebral amyloid angiopathy¹⁰. Similarly, the

presence of CMBs was associated with a higher risk of developing new ischaemic strokes than of ICH in a European cohort of patients with ischaemic stroke or TIA¹⁴.

CMBs and antithrombotic therapy

Antiplatelet treatment, and to a greater extent anticoagulant treatment, increase the risk of ICH in patients with CMBs². In two large prospective cohorts, patients with a high CMB burden and on antiplatelet therapy following ischaemic stroke or TIA had increased risk of both ischaemic and haemorrhagic stroke [16]. In a prospective observational study of patients on anticoagulation therapy for AF with ischaemic stroke or TIA (CROMIS-2), the presence of CMBs at baseline was independently associated with increased risk for symptomatic ICH (sICH rate - 9.8 per 1000 patient-years with CMBs compared to 2.6 without CMBs)²². In the NAVIGATE-ESUS trial, use of rivaroxaban in patients with cryptogenic stroke was associated with a 4-fold increase in the risk of ICH, and the risk was greater with a higher CMB burden²³. Some studies have reported higher rates of ICH, disability and mortality in patients with >10 CMBs when treated with intravenous thrombolysis for ischaemic stroke, especially in older age and with longer treatment delays²⁴. However, others have not found similar increased bleeding risks with thrombolysis²⁵.

CMBs – To treat or not to treat?

Patients with recent ischaemic stroke or TIA are at risk of recurrent ischaemic events, but the risk of ICH with antithrombotic therapy is greater in the presence of CMBs. This has led to a therapeutic conundrum in patients with a history of stroke and CMBs detected on MRI, with concerns expressed regarding the use of antithrombotic treatment, especially anticoagulants^{2,16,23}. It has been suggested that patients with lobar ICHs and numerous lobar CMBs, with the possibility of underlying CAA and associated high risk of rebleeding, should not receive anticoagulants².

However, there is increasing evidence that CMBs are not only markers of a haemorrhage-prone arteriopathy but also markers of recurrent ischaemic events¹². Recent data has shown that the absolute risk of recurrent ischaemic stroke is higher than the risk of ICH in patients with ischaemic stroke or TIA and CMBs, even with a high CMB burden^{10,22,23,26}. In a pooled analysis of data from 38 cohort studies in the Microbleeds International Collaborative Network, the rate of recurrent ischaemic stroke was 64/1000 person-years, compared to symptomatic ICH rate of 27/1000 person-years, in the presence of ≥ 10 CMBs¹⁰. In the CROMIS-2 study of patients on anticoagulation therapy for AF following ischaemic stroke or TIA, the absolute event rate of

ischaemic stroke in patients with CMBs (24.1 per 1000 patient-years) was much higher than the absolute event rate of symptomatic ICH (9.8 per 1000 patient-years)²². A recent study of patients with acute ischaemic stroke and AF treated with oral anticoagulants has yielded similar results. The presence and burden of CMBs were associated with an increase in vascular events (ICH, ischaemic stroke or vascular death) on long term follow up, and the absolute rates of ischaemic stroke were higher than those of ICH at all levels of CMB burden²⁶. In a subgroup analysis of the NAVIGATE-ESUS trial, the presence of CMBs did not influence the risk of ICH in patients with cryptogenic stroke treated with rivaroxaban²³. Further, no interaction was noted between single or dual antiplatelet therapy and the presence of CMBs for the outcomes of recurrent ischaemic or haemorrhagic stroke in patients with lacunar infarcts in the SPS3 trial⁷. More recent data demonstrate that starting antiplatelet treatment may not be associated with an increased risk of bleeding in the presence of CMBs even in patients with ICH. In the RESTART trial, CMB presence, burden or location was not associated with a higher risk of recurrent ICH in patients treated with antiplatelet therapy following an ICH²⁷.

These data suggest that the CMB presence, pattern or burden should not influence the decision to select appropriate antithrombotic therapy for secondary stroke prevention. Withholding antithrombotic treatment based on the presence of CMBs is not supported by current evidence^{10,12,23,26,28}.

CMBs – more uncertainties

Management of patients with CMBs poses several more therapeutic dilemmas. Several factors such as blood pressure variability and control and concurrent anti-thrombotic drug use can increase ICH risk, in addition to the presence of CMBs. There is no data regarding their relative contribution to ICH risk⁷. The ongoing APACHE-AF trial is expected to provide more insights into the use of NOACs in patients with AF and a recent ICH²⁹.

There is a well-known geographical variation in ICH risk, with ICH being commoner in Asian, especially Far Eastern, populations. Their vascular risk factor profile is different, with a higher prevalence of hypertensive arteriopathy. Asians also have a higher CMB prevalence compared to Western populations, in both ischaemic stroke and ICH patient groups^{12,16,23}. Their CMB distribution is different, with higher rates of non-lobar (deep or infratentorial) CMBs, and hypertensive arteriopathy rather than CAA is believed to contribute to the elevated ICH risk in Asians³⁰. The balance of risk for developing ICH compared to ischaemic stroke in the presence of CMBs appears to be different between Asian and Western populations, with Asians with CMBs more likely to develop ICH and Western populations more likely

to develop ischaemic stroke¹¹. Further studies are needed to better understand the complex effects of ethnicity and genetics on CMB prevalence and associated ICH risk.

Of particular interest are the intriguing results of a recent study which identified *Streptococcus mutans*, an oral pathogen responsible for dental caries, in a large number of stroke patients with CMBs, suggesting a possible association between the oral microbiome and cerebral microbleeds³¹. It has been postulated that *S. mutans* expressing the *cnm* gene can enter the blood stream from the oral cavity, attach to the cerebral vasculature, disrupt the blood-brain barrier, and lead to the development of CMBs³¹. This raises the exciting possibility of treating CMBs with antibiotics to reduce stroke risk.

Key learning points

- Cerebral microbleeds (CMBs) are a radiological biomarker of cerebral microangiopathy.
- Lobar CMBs are associated with cerebral amyloid angiopathy in superficial perforating arteries, and subcortical CMBs with hypertensive arteriopathy in deep perforating arteries.
- CMBs are more prevalent in patients with both haemorrhagic stroke and ischaemic stroke, and are a marker for small vessel disease.
- In patients with intracerebral haemorrhage (ICH), CMBs increase risk of recurrent ICH, and in patients with ischaemic stroke, CMBs increase risk of recurrent stroke, both ischaemic and haemorrhagic.
- The absolute event rate is higher for ischaemic stroke than for ICH in patients with stroke and CMBs.
- There is no evidence to support a policy of withholding antithrombotic treatment in patients with stroke and CMBs.

References

1. Wardlaw JM, Lewis SC, Keir SL, Dennis MS, Shenkin S. Cerebral microbleeds are associated with lacunar stroke defined clinically and radiologically, independently of white matter lesions. *Stroke* 2006; **37**: 2633-6. doi: 10.1161/01.STR.0000240513.00579.bf.
2. Boyano I, Bravo N, Miranda J, Gil-Gregorio P, Olazarán J. Brain microbleeds: Epidemiology and clinical implications. *Neurología*. 2018; **33**: 515-25.
3. Greenberg SM, Vernooij MW, Cordonnier C, Viswanathan A, Al-Shahi Salman R, Warach S, Launer LJ, Van Buchem MA, Breteler MM; Microbleed Study Group. Cerebral microbleeds: a guide to detection and interpretation. *Lancet Neurol*. 2009; **8**: 165-74. doi: 10.1016/S1474-4422(09)70013-4.

4. Viswanathan A, Chabriat H. Cerebral microhemorrhage. *Stroke* 2006; **37**: 550-5. doi: 10.1161/01.STR.0000199847.96188.12.
5. Ikram MA, van der Lugt A, Niessen WJ, Krestin GP, Koudstaal PJ, Hofman A, Breteler MM, Vernooij MW. The Rotterdam Scan Study: design and update up to 2012. *Eur J Epidemiol.* 2011; **26**: 811-24. doi: 10.1007/s10654-011-9624-z.
6. Vernooij MW, van der Lugt A, Ikram MA, Wielopolski PA, Niessen WJ, Hofman A, Krestin GP, Breteler MM. Prevalence and risk factors of cerebral microbleeds: the Rotterdam Scan Study. *Neurology* 2008; **70**: 1208-14. doi: 10.1212/01.wnl.0000307750.41970.d9.
7. Charidimou A, Imaizumi T, Moulin S, Biffi A, Samarasekera N, Yakushiji Y, et al. Brain hemorrhage recurrence, small vessel disease type, and cerebral microbleeds: A meta-analysis. *Neurology* 2017; **89**: 820-9. doi: 10.1212/WNL.0000000004259.
8. Saito T, Kawamura Y, Sato N, Kano K, Takahashi K, Asanome A, Sawada J, Katayama T, Hasebe N. Non-vitamin k antagonist oral anticoagulants do not increase cerebral microbleeds. *J Stroke Cerebrovasc Dis.* 2015; **24**: 1373-7. doi: 10.1016/j.jstrokecerebrovasdis.2015.02.018.
9. Shoamanesh A, Kwok CS, Benavente O. Cerebral microbleeds: histopathological correlation of neuroimaging. *Cerebrovasc Dis.* 2011; **32**: 528-34. doi: 10.1159/000331466.
10. Wilson D, Ambler G, Lee KJ, Lim JS, Shiozawa M, Koga M, et al. Microbleeds International Collaborative Network. Cerebral microbleeds and stroke risk after ischaemic stroke or transient ischaemic attack: a pooled analysis of individual patient data from cohort studies. *Lancet Neurol.* 2019; **18**: 653-65. doi: 10.1016/S1474-4422(19)30197-8.
11. Charidimou A, Kakar P, Fox Z, Werring DJ. Cerebral microbleeds and recurrent stroke risk: systematic review and meta-analysis of prospective ischemic stroke and transient ischemic attack cohorts. *Stroke* 2013; **44**: 995-1001. doi: 10.1161/STROKEAHA.111.000038.
12. Cordonnier C, Al-Shahi Salman R, Wardlaw J. Spontaneous brain microbleeds: systematic review, subgroup analyses and standards for study design and reporting. *Brain* 2007; **130**: 1988-2003. doi: 10.1093/brain/awl387.
13. Charidimou A, Shams S, Romero JR, Ding J, Veltkamp R, Horstmann S, et al. International META-MICROBLEEDS Initiative. Clinical significance of cerebral microbleeds on MRI: A comprehensive meta-analysis of risk of intracerebral hemorrhage, ischemic stroke, mortality, and dementia in cohort studies. *Int J Stroke* 2018; **13**: 454-68. doi: 10.1177/1747493017751931
14. Thijs V, Lemmens R, Schoofs C, Görner A, Van Damme P, Schrooten M, Demaerel P. Microbleeds and the risk of recurrent stroke. *Stroke* 2010; **41**(9): 2005-9. doi: 10.1161/STROKEAHA.110.588020.
15. Kim BJ, Yoon Y, Sohn H, et al. Difference in the location and risk factors of cerebral microbleeds according to ischemic stroke subtypes. *J Stroke* 2016; **18**: 297-303. doi: <https://doi.org/10.5853/jos.2016.00360>
16. Lau KK, Lovelock CE, Li L, Simoni M, Gutnikov S, Küker W, et al. Antiplatelet treatment after transient ischemic attack and ischemic stroke in patients with cerebral microbleeds in 2 large cohorts and an updated systematic review. *Stroke* 2018; **49**: 1434-42.
17. Shoamanesh A, Pearce LA, Bazan C, Catanese L, McClure LA, Sharma M, et al. SPS3 Trial Investigators. Microbleeds in the Secondary Prevention of Small Subcortical Strokes Trial: Stroke, mortality, and treatment interactions. *Ann Neurol.* 2017; **82**: 196-207. doi: 10.1002/ana.24988.
18. Imaizumi T, Horita Y, Hashimoto Y, Niwa J. Dotlike hemosiderin spots on T2*-weighted magnetic resonance imaging as a predictor of stroke recurrence: a prospective study. *J Neurosurg.* 2004; **101**: 915-20.
19. Wang J, Zhang J, Shen Y, Xu X. The safety of antithrombotic therapy in patients with cerebral microbleeds and cardiogenic cerebral embolism due to nonvalvular atrial fibrillation. *BMC Cardiovasc Disord.* 2019; **19**: 77. doi: 10.1186/s12872-019-1046-y.
20. Cheng Y, Liu J, Zhang S, Li J, Wei C, Wang D, et al. Prior Antithrombotic Therapy Is Associated with Cerebral Microbleeds in Ischemic Stroke Patients with Atrial Fibrillation and/or Rheumatic Heart Disease. *Front Neurol.* 2019; **9**: 1184. doi: 10.3389/fneur.2018.01184.
21. Saito T, Kawamura Y, Tanabe Y, Asanome A, Takahashi K, Sawada J, et al. Cerebral microbleeds and asymptomatic cerebral infarctions in patients with atrial fibrillation. *J Stroke Cerebrovasc Dis.* 2014; **23**: 1616-22. doi: 10.1016/j.jstrokecerebrovasdis.2014.01.005.
22. Wilson D, Ambler G, Shakeshaft C, Brown MM, Charidimou A, Al-Shahi Salman R, et al. CROMIS-2 collaborators. Cerebral microbleeds and intracranial haemorrhage risk in patients anticoagulated for atrial fibrillation after acute ischaemic stroke or transient ischaemic attack (CROMIS-2): a multicentre observational cohort study. *Lancet Neurol.* 2018; **17**: 539-47. doi: 10.1016/S1474-4422(18)30145-5
23. Shoamanesh A, Hart RG, Connolly SJ, Kasner SE, Smith EE, Martí-Fàbregas J et al. Microbleeds and the Effect of Anticoagulation in Patients with Embolic Stroke of Undetermined Source: An Exploratory Analysis of the NAVIGATE ESUS Randomized Clinical Trial. *JAMA Neurol.* 2020: e203836. doi: 10.1001/jamaneurol.2020.3836.
24. Schlemm L, Endres M, Werring DJ, Nolte CH. Benefit of Intravenous Thrombolysis in Acute Ischemic Stroke Patients with High Cerebral Microbleed Burden. *Stroke* 2020; **51**: 232-9. doi: 10.1161/STROKEAHA.119.027633.
25. Kakuda W, Thijs VN, Lansberg MG, Bammer R, Wechsler L, Kemp S, et al. DEFUSE Investigators. Clinical importance of microbleeds in patients receiving IV thrombolysis. *Neurology.* 2005; **65**: 1175-8. doi: 10.1212/01.wnl.0000180519.27680.0f.
26. Choi KH, Kim JH, Lee C, Kim JM, Kang KW, Kim JT, et al. Microbleeds and Outcome in Patients With Acute Ischemic Stroke and Atrial Fibrillation Taking Anticoagulants. *Stroke* 2020; **51**: 3514-22. doi: 10.1161/STROKEAHA.120.030300.

27. Al-Shahi Salman R, Minks DP, Mitra D, Rodrigues MA, Bhatnagar P, du Plessis JC, et al; RESTART Collaboration. Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial. *Lancet Neurol*. 2019; **18**: 643-52. doi: 10.1016/S1474-4422(19)30184-X.
28. Tsivgoulis G, Katsanos AH. Can cerebral microbleeds predict stroke recurrence? *Lancet Neurol*. 2019; **18**: 619-20. doi: 10.1016/S1474-4422(19)30194-2.
29. van Nieuwenhuizen KM, van der Worp HB, Algra A, Kappelle LJ, Rinkel GJ, van Gelder IC, et al. APACHE-AF Investigators. Apixaban versus Antiplatelet drugs or no antithrombotic drugs after anticoagulation-associated intracerebral Haemorrhage in patients with Atrial Fibrillation (APACHE-AF): study protocol for a randomised controlled trial. *Trials* 2015; **16**: 393. doi: 10.1186/s13063-015-0898-4.
30. Yakushiji Y, Wilson D, Ambler G, Charidimou A, Beiser A, van Buchem MA, et al. Distribution of cerebral microbleeds in the East and West: Individual participant meta-analysis. *Neurology* 2019; **92**: e1086-e97. doi: 10.1212/WNL.0000000000007039.
31. Hosoki S, Saito S, Tonomura S, et al. Oral carriage of *Streptococcus mutans* harboring the *cnm* gene relates to an increased incidence of cerebral microbleeds. *Stroke* 2020; **51**: XXX-XXX. doi: 10.1161/STROKEAHA.120.029607